August 19, 2017 9:07 PM ET

Biotechnology

Company Overview of Padlock Therapeutics, Inc.

Company Overview

Padlock Therapeutics, Inc. is a biotechnology company that develops new medicines for destructive autoimmune diseases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The company was founded in 2014 and is based in Cambridge, Massachusetts. As of April 1, 2016, Padlock Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company.

200 Cambridge Park Drive

Cambridge, MA 02140

United States

Founded in 2014

Phone:

978-381-9601

Key Executives for Padlock Therapeutics, Inc.

Founder and Chief Executive Officer
Age: 62
Head of Biology
Director of Biology
Chief Scientific Officer
Compensation as of Fiscal Year 2017.

Padlock Therapeutics, Inc. Key Developments

Padlock Therapeutics, Inc. Presents at 9th Annual BioPharm America International Partnering Conference - BioPharm America 2016, Sep-14-2016 12:30 PM

Padlock Therapeutics, Inc. Presents at 9th Annual BioPharm America International Partnering Conference - BioPharm America 2016, Sep-14-2016 12:30 PM. Venue: Marriott Copley Place, Boston, Massachusetts, United States. Speakers: Michael Gilman, Founder, Chief Executive Officer and Director.

Padlock Therapeutics Appoints Kerri Mowen as Director of Biology

Padlock Therapeutics announced the appointment of Kerri Mowen, Ph.D., one of the Company's scientific co-founders, to the newly created position of Director of Biology. Dr. Mowen is a leading expert in the biology of protein-arginine deiminase (PAD) enzymes.

Padlock Therapeutics Appoints Adelene Q. Perkins as Independent Member of Board of Directors

Padlock Therapeutics announced the appointment of Adelene Q. Perkins, chairman and chief executive officer of Infinity Pharmaceuticals, Inc., as the first independent member of the company’s Board of Directors. Ms. Perkins is a highly-regarded biopharmaceutical industry executive with 25 years of international business and corporate strategy experience, focused on licensing and business development, strategic finance, product life cycle management, and building and leading high-caliber, cross-functional teams. Ms. Perkins has played an integral role leading Infinity in its transition from a private, platform-based to a publicly-traded, product-based organization. She has been instrumental in developing Infinity’s business strategy, including the establishment of innovative strategic partnerships.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States
Bertelsmann AG Europe
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Padlock Therapeutics, Inc., please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.